Introduction {#sec1}
============

Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor approved for the treatment of metastatic ER+/HER2- breast cancer.[@bib1], [@bib2], [@bib3] The interaction of cyclin D with CDK4 and CDK6 results in the hyperphosphorylation of the retinoblastoma gene product, which ultimately leads to progression from G1 to the S phase of the cell cycle.[@bib4] Palbociclib-induced inhibition of CDK4/6 prevents cell cycle progression and thus halts uncontrolled cancer cell division.

Preclinical data suggest palbociclib may augment the therapeutic effect of radiation therapy (RT) via multiple methods.[@bib5], [@bib6], [@bib7] Despite this potential benefit, clinicians seldom use this combination out of fear that RT may exacerbate palbociclib toxicity, particularly neutropenia and leukopenia. We report the preliminary results of patients who received RT while being treated with palbociclib for metastatic breast cancer.

Methods and Materials {#sec2}
=====================

With institutional review board approval, we retrospectively reviewed records of all patients who were treated with palbociclib at Rush University Medical Center from 2015 to 2018. The starting palbociclib dose was 125 mg daily from day 1 to 21 in association with either fulvestrant 500 mg every 28 days or letrozole 2.5 mg daily. Patients who received RT for symptomatic metastasis concurrently or within 14 days of palbociclib administration (mean half-life of 26 hours[@bib8]) were included in our analysis.

Patient charts were reviewed for the following baseline patient and treatment characteristics: age, sex, Eastern Cooperative Oncology Group performance status, laboratory values, treatment site, RT technique (3-dimensional conformal RT, intensity modulated RT, whole brain radiation therapy \[WBRT\], fractionated stereotactic radiosurgery \[fSRS\], stereotactic body RT) and radiation dose/fractionation.

Pain relief was assessed by the patient\'s self-rated pain scores (range, 0 \[no pain\] to 10 \[worst pain ever\]). Local treatment effect was determined by subsequent computed tomography or magnetic resonance imaging, if applicable. Toxicity was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 during the weekly clinic and follow-up visits in the radiation or medical oncology departments.

Results {#sec3}
=======

Patient and treatment characteristics {#sec3.1}
-------------------------------------

A total of 16 women (median age, 59.6 \[range, 33.3-91.0\] years) received palliative RT in close temporal association with palbociclib ([Table 1](#tbl1){ref-type="table"}). The median duration of palbociclib use was 15.7 months (1.9-38.0). The median time of closest palbociclib use to RT administration was 5 days (range, 0-14): 4 patients received palbociclib before RT (25.0%), 5 (31.3%) concurrently, and 7 (43.8%) after RT.Table 1Baseline patient characteristicsParametersn (range) or median (range)Prior breast RT8 (50%)Prior chemotherapy8 (50%)Prior hormone therapy10 (62.5%)Age at RT, y59.6 (33.3-91.0)Palbociclib + Fulvestrant6 (37.5%) Letrozole10 (62.5%)Closest palbociclib to RT interval (d)5 (0-14)Closest palbociclib proximity to RT Prior4 (25.0%) Concurrent5 (31.3%) Post7 (43.8%)RT site Bone: axial skeleton (vertebra)9 (39.1%) Bone: axial skeleton (other)2 (8.7%) Bone: pelvis4 (17.4%) Bone: extremity3 (13.0%) Brain4 (17.4%) Mediastinum1 (4.3%)[^1]

The following sites were treated in order of frequency: bone (11 axial skeleton \[9 vertebra; 2 other\]; 4 pelvis; 3 extremity), brain (4: 3 WBRT and 1 fSRS), and mediastinum (1). Sixteen of 18 osseous sites received conventional RT (range, 30-37.5 Gy/10-15 fractions fxn), whereas 2 received stereotactic body RT (18 Gy/1 fxn and 30 Gy/3 fxn). For brain, WBRT ranged from 30 to 35 Gy in 10 to 14 fxn and fSRS brain dose was 25 Gy in 5 fxn. The patient treated to the mediastinum received 36 Gy in 18 fxn. [Table 2](#tbl2){ref-type="table"} shows full RT treatment characteristics for each patient.Table 2RT treatment characteristicsPatientRT siteRT techniqueRT dose/fxnPain reliefLR1C2SBRT18 Gy/1 fxnYesNo2Left iliac crestSBRT30 Gy/3 fxnYesNo3C2-C73D-CRT30 Gy/10 fxnYesNo4Right shoulder3D-CRT30 Gy/10 fxnYesNoBilateral knees3D-CRT30 Gy/10 fxnNo5T12-L23D-CRT30 Gy/10 fxnYesNoLeft hip3D-CRT30 Gy/10 fxnNo6T8-L13D-CRT35 Gy/14 fxnYesNo7T6-83D-CRT35 Gy/14 fxnYesNoRight calvariumIMRT37.5 Gy/15 fxnNo8L3-sacrum3D-CRT35 Gy/14 fxnYesNoRight hip3D-CRT35 Gy/14 fxnNoLeft ribs3D-CRT35 Gy/14 fxnNo9L-S spine3D-CRT35 Gy/14 fxnYesNoRight hemipelvis3D-CRT35 Gy/14 fxnNoRight proximal femur3D-CRT35 Gy/14 fxnNo10L3-sacrum3D-CRT30 Gy/10 fxnYesNo11T10-T123D-CRT30 Gy/10 fxnYesNo12Left frontal cavityfSRS25 Gy/5 fxn-No13BrainWBRT30 Gy/10 fxn-No14BrainWBRT35 Gy/14 fxn\--15BrainWBRT30 Gy/10 fxn\--16MediastinumIMRT36 Gy/18 fxnYesNo[^2]

Treatment outcomes and toxicity {#sec3.2}
-------------------------------

At the most recent follow-up, 12 patients are still living. The median and mean time from RT to last known follow-up or death is 14.7 and 17.6 months (range, 1.7-38.2), respectively. Median pre-RT pain was 8 (range, 6-10). Pain relief was achieved in all patients (median: 2 \[range, 0-3\]). No radiographic local failure was noted in the 13 patients with evaluable follow-up imaging.

The combination of RT and palbociclib was well-tolerated. Grade 1 fatigue, dermatitis, and nausea were noted in 5, 3, and 1 patient, respectively. One patient who underwent WBRT developed grade 1 headache. No acute or late grade 2 or higher cutaneous, neurologic, or gastrointestinal toxicities were noted.

[Table 3](#tbl3){ref-type="table"} shows hematologic parameters before and after RT. The median time interval from blood draw and RT was 12 days (0-40) and 8 days (1-47) for pre- and postvalues, respectively. The median pre- and post-RT white blood cell (normal, 4.0-10.0 k/uL), neutrophil (normal, 1.84-7.8 K/uL), and platelet count (normal, 150-399 K/uL) was 5.12 and 4.8, 2.83 and 3.19, and 250 and 210, respectively. Leukopenia, neutropenia, and thrombocytopenia were seen in 4 (25.0%), 5 (31.3%), and 1 (6.3%) patients before RT. After RT, 5 (31.3%; 4 new \[3 grade 1 and 1 grade 2\]), 1 (6.3%; grade 2), and 3 (18.8%; grade 1) patients were leukopenic, neutropenic, and thrombocytopenic, respectively.Table 3Hematologic parameters before and after RT in patients receiving palbociclibPatientIrradiated Site(s)Palbo-RT relationHematologic parameters[∗](#tbl3fnlowast){ref-type="table-fn"}Pre-RTPost-RTWBC countLeukopeniaNeutrophil countNeutropeniaPlatelet countThrombocytopeniaWBC countLeukopeniaNeutrophil countNeutropeniaPlatelet countThrombocytopenia1AxialPost7.24No5.02No404No5.10No2.26No375No2PelvisC5.78No3.34No247No5.23No3.25No247No3AxialPre3.05Yes1.07Yes139Yes4.74No3.19No193No4ExtremityPost1.72Yes0.76Yes198No1.35Yes2.46No167No5Axial + pelvisPost2.66Yes1.07Yes181No5.14No3.78No210No6AxialC4.13No2.64No334No4.80No3.29No313No7AxialPre8.91No4.86No420No7.73No6.08No165No8Axial + pelvisC4.83No3.22No262No2.20Yes1.28Yes120Yes9Axial + pelvis + extremityPost8.74No5.09No255No4.82No3.20No226No10AxialPre6.30No3.62No196No9.20No6.90No139Yes11AxialPost3.26No1.09Yes181No3.32Yes1.93No216No12BrainC5.30No3.30No175No4.46No2.14No259No13BrainPost5.51No2.81No350No9.31No6.69No172No14BrainPost5.58No2.84No475No3.12Yes2.04No119Yes15BrainPre3.60Yes1.42Yes195No\-\-\-\-\--16MediastinumC4.94No2.72No253No3.88Yes2.78No211No[^3][^4]

No patients developed infections after RT. All but 2 (grade 2) hematologic toxicities were grade 1. There was no difference in toxicities based on palbociclib-RT sequencing or by irradiated site.

Discussion {#sec4}
==========

Palbociclib is the first CDK 4/6 inhibitor approved for metastatic ER+/HER2- breast cancer based on the promising results of the PALOMA studies. Preclinical evidence suggests that palbociclib may act synergistically with RT. Palbociclib-induced inhibition of CDK4/6 prevents cell cycle progression to the more radioresistant S phase. Moreover, palbociclib can act as a DNA double-strand break repair inhibitor,[@bib7] thus amplifying the anticancer effect of RT.

The most frequently seen toxicity with palbociclib is hematologic, which can also occur after irradiation. Many patients with metastatic breast cancer become symptomatic and need RT; however, the lack of published clinical toxicity data results in physician reluctance to administer RT to patients receiving palbociclib.

Therefore, we examined the safety and efficacy of concomitant palbociclib and RT in 16 patients with breast cancer with symptomatic metastases. With a median follow-up time of 14.7 months, we report no significant increase in acute or late toxicities, particularly hematologic, with this novel combination as compared to reports of palbociclib alone. Additionally, no differences were seen when assessing toxicity based on irradiated site (axial vs pelvis vs other) or palbociclib-RT relation (pre-, post-, and concurrent; [Table 3](#tbl3){ref-type="table"}). Sustained pain relief was achieved in all patients, and no local failures were seen in the evaluable patients.

After exhaustive literature review, we found only 1 published study investigating this combination in humans. Consistent with our findings, Hans et al[@bib9] also report no increase in toxicity in 5 patients treated with palbociclib and RT; however, their study does not report follow-up time, local control, or toxicities grouped by irradiated site or proximity of RT and palbociclib administration.

Preclinical studies of palbociclib and RT in nonbreast cancer also seem to be promising. Two studies[@bib6], [@bib10] of palbociclib and RT in glioblastoma cell lines showed increased tumor cell apoptosis with the combination compared to monotherapy. Another study showed that palbociclib sensitized both tumor cell lines and autochthonous mouse tumors to radiation in medulloblastoma.[@bib5] Similar results are seen in hepatocellular carcinoma,[@bib7] cholangiocarcinoma, and non-small cell lung cancer[@bib11] cell lines. Jointly, these studies suggest that palbociclib may be a promising drug to increase the therapeutic ratio of RT.

Conclusions {#sec5}
===========

The use of RT in patients with metastatic breast cancer receiving palbociclib resulted in minimal grade 1 to 2 and no grade 3+ toxicities. This preliminary work suggests that RT in this patient population is safe and feasible. Subsequent studies with longer follow-up are needed to confirm these results and investigate further use of palbociclib with RT.

Preliminary results from this study were presented in part as a Spotlight presentation at the 2018 San Antonio Breast Cancer Symposium, San Antonio, TX, December 7, 2018.
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[^1]: *Abbreviation:* RT = radiation therapy.

[^2]: *Abbreviations:* 3D-CRT = 3-dimensional conformal radiation therapy; C = cervical; fSRS = fractionated stereotactic radiosurgery; Fxn = fraction; IMRT = intensity modulated radiation therapy; L = lumbar; LR = local recurrence; RT = radiation therapy; SBRT = stereotactic body radiation therapy; T = thoracic; WBRT = whole brain radiation therapy.

[^3]: *Abbreviations:* C = concurrent with RT; Palbo = palbociclib; RT = radiation therapy; WBC = white blood cell.

[^4]: WBC, neutrophil, and platelet count measured in K/uL. Normal WBC range: 4.00-10.00 K/uL. Normal neutrophil range: 1.84-7.80 K/uL. Normal platelet range: 150-399 K/uL.
